ALLMedicine™ Prostatectomy Center

May 20th, 2022 - Background: Immune checkpoint inhibitors interfere with the immune system s autoregulatory mechanisms, allowing for a potentially expanded and prolonged T-cell response with the possibility of greater antitumor effects. Nivolumab is a fully human ...

May 20th, 2022 - Background: About 30,000 men will die from prostate cancer in the US in 2018. The majority of these men originally presented with localized cancer. Treatment options for patients with high risk, localized disease typically involve radical prostate...

May 20th, 2022 - Background: Pilot study to evaluate the feasibility of real time ultrasound imaging to guide focal thermal ablation of low risk focal prostate tumors Prostate cancer is relatively slow growing, with doubling times for local tumors estimated at 2 t...

May 20th, 2022 - Background: Multiparametric MRI (mpMRI) has become an established method for localizing clinically significant prostate cancer, and identification of imaging-based prognostic markers represents an active research area. Multiple treatments are avai...

May 20th, 2022 - Background: Prostate cancer that recurs after prior radiation treatment can be challenging to cure due to the side effects of available treatments such as surgery and cryoablation. Re-irradiation with brachytherapy or stereotactic approaches has s...

Nov 14th, 2020 - Prostate bed (PB) irradiation is considered the standard postoperative treatment after radical prostatectomy (RP) for tumors with high-risk features or persistent prostate-specific antigen, or for salvage treatment in case of biological relapse. F...

Jun 27th, 2020 - Controversies and uncertainty persist in prostate cancer grading. To update grading recommendations. Critical review of the literature along with pathology and clinician surveys. Percent Gleason pattern 4 (%GP4) is as follows: (1) report %GP4 in n...

May 2nd, 2019 - The purpose of this amendment is to incorporate newly-published literature into the original ASTRO/AUA Adjuvant and Salvage Radiotherapy after Prostatectomy Guideline and to provide an updated clinical framework for clinicians. The original system...

May 5th, 2018 - Diagnosis and management of prostate cancer post treatment is a large and complex problem, and care of these patients requires multidisciplinary involvement of imaging, medical, and surgical specialties. Imaging capabilities for evaluation of men ...

Jul 2nd, 2017 - These guidelines cover a wide range of topics from prostate cancer epidemiology to palliative care. Questions arising in daily clinical practice have been extracted and formulated as clinical questions. In the 4 years since the previous edition, t...

May 20th, 2022 - Background: About 30,000 men will die from prostate cancer in the US in 2018. The majority of these men originally presented with localized cancer. Treatment options for patients with high risk, localized disease typically involve radical prostate...

May 20th, 2022 - Background: Pilot study to evaluate the feasibility of real time ultrasound imaging to guide focal thermal ablation of low risk focal prostate tumors Prostate cancer is relatively slow growing, with doubling times for local tumors estimated at 2 t...

May 20th, 2022 - Background: Immune checkpoint inhibitors interfere with the immune system s autoregulatory mechanisms, allowing for a potentially expanded and prolonged T-cell response with the possibility of greater antitumor effects. Nivolumab is a fully human ...

May 20th, 2022 - Background: Multiparametric MRI (mpMRI) has become an established method for localizing clinically significant prostate cancer, and identification of imaging-based prognostic markers represents an active research area. Multiple treatments are avai...

May 20th, 2022 - Background: Prostate cancer that recurs after prior radiation treatment can be challenging to cure due to the side effects of available treatments such as surgery and cryoablation. Re-irradiation with brachytherapy or stereotactic approaches has s...

Mar 1st, 2022 - Robotic prostate surgery pioneer Mani Menon, MD, is joining Mount Sinai and will serve as Chief of Strategy and Innovation in the Department of Urology for the Mount Sinai Health System. He will also serve as a Professor of Urology, Director of Ed...

Mar 1st, 2022 - Darolutamide (Nubeqa) produced a well-tolerated safety profile in patients with metastatic castration-resistant prostate cancer (mCRPC), according to pooled data from long-term analyses of 3 trials.1 The analysis from first author Egils Vjaters, ...

Mar 1st, 2022 - Patients with a urological cancer who were also infected with COVID-19 and undergoing elective surgery for their disease, were found to have a significantly higher likelihood of experiencing respiratory complications and mortality than those witho...

Feb 18th, 2022 - The utilization of 18F-rhPSMA-7.3 imaging displayed a clinically meaningful correct detection rate (CDR), meeting the prespecified threshhold of assessing suspected biochemical recurrence in prostate cancer, according to findings from the phase 3 ...

Feb 15th, 2022 - Key clinical point: Use of nonselective beta-blockers at the time of radical prostatectomy is associated with a lower odds of treatment initiation for recurrence in patients with prostate cancer. Major finding: The use of nonselective beta-blocker.